XML 44 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segments of Business and Geographic Areas (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Sales By Segment Of Business
SALES BY SEGMENT OF BUSINESS
 
 
Fiscal Third Quarters Ended
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 30,
2018
 
October 1,
2017
 
Percent
Change
 
September 30,
2018
 
October 1,
2017
 
Percent Change
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
$
120

 
100

 
20.0
 %
 
$
306

 
326

 
(6.1
)%
     International
 
352

 
377

 
(6.6
)
 
1,079

 
1,100

 
(1.9
)
     Worldwide
 
472

 
477

 
(1.0
)
 
1,385

 
1,426

 
(2.9
)
Beauty
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
543

 
523

 
3.8

 
1,791

 
1,739

 
3.0

     International
 
535

 
510

 
4.9

 
1,480

 
1,351

 
9.5

     Worldwide
 
1,078

 
1,033

 
4.4

 
3,271

 
3,090

 
5.9

Oral Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
158

 
154

 
2.6

 
472

 
460

 
2.6

     International
 
226

 
228

 
(0.9
)
 
684

 
678

 
0.9

     Worldwide
 
384

 
382

 
0.5

 
1,156

 
1,138

 
1.6

OTC
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
440

 
401

 
9.7

 
1,359

 
1,310

 
3.7

     International
 
608

 
601

 
1.2

 
1,827

 
1,711

 
6.8

     Worldwide
 
1,048

 
1,002

 
4.6

 
3,186

 
3,021

 
5.5

Women's Health
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3

 
3

 
0.0

 
10

 
9

 
11.1

     International
 
266

 
267

 
(0.4
)
 
782

 
779

 
0.4

     Worldwide
 
269

 
270

 
(0.4
)
 
792

 
788

 
0.5

Wound Care/Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
106

 
104

 
1.9

 
344

 
342

 
0.6

     International
 
58

 
88

 
(34.1
)
 
183

 
257

 
(28.8
)
     Worldwide
 
164

 
192

 
(14.6
)
 
527

 
599

 
(12.0
)
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,370

 
1,285

 
6.6

 
4,282

 
4,186

 
2.3

     International
 
2,045

 
2,071

 
(1.3
)
 
6,035

 
5,876

 
2.7

     Worldwide
 
3,415

 
3,356

 
1.8

 
10,317

 
10,062

 
2.5

 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,400

 
2,420

 
(0.8
)
 
6,717

 
6,644

 
1.1

     International
 
998

 
849

 
17.6

 
3,061

 
2,514

 
21.8

     Worldwide
 
3,398

 
3,269

 
3.9

 
9,778

 
9,158

 
6.8

     REMICADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
987

 
1,206

 
(18.2
)
 
2,821

 
3,452

 
(18.3
)
     U.S. Exports
 
100

 
156

 
(35.9
)
 
346

 
448

 
(22.8
)
     International
 
292

 
285

 
2.5

 
921

 
949

 
(3.0
)
     Worldwide
 
1,379

 
1,647

 
(16.3
)
 
4,088

 
4,849

 
(15.7
)
 
 
 
 
 
 
 
 
 
 
 
 
 
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
281

 
242

 
16.1

 
779

 
701

 
11.1

     International
 
255

 
234

 
9.0

 
823

 
642

 
28.2

     Worldwide
 
536

 
476

 
12.6

 
1,602

 
1,343

 
19.3

     STELARA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
889

 
800

 
11.1

 
2,460

 
2,027

 
21.4

     International
 
421

 
324

 
29.9

 
1,252

 
903

 
38.6

     Worldwide
 
1,310

 
1,124

 
16.5

 
3,712

 
2,930

 
26.7

     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
143

 
16

 
*
 
311

 
16

 
*
     International
 
30

 
6

 
*
 
65

 
20

 
*
     Worldwide
 
173

 
22

 
*
 
376

 
36

 
*
 
 
 
 
 
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
345

 
353

 
(2.3
)
 
1,006

 
1,020

 
(1.4
)
     International
 
478

 
460

 
3.9

 
1,496

 
1,334

 
12.1

     Worldwide
 
823

 
813

 
1.2

 
2,502

 
2,354

 
6.3

     EDURANT® / rilpivirine
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
13

 
15

 
(13.3
)
 
42

 
44

 
(4.5
)
     International
 
189

 
179

 
5.6

 
581

 
478

 
21.5

     Worldwide
 
202

 
194

 
4.1

 
623

 
522

 
19.3

     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
297

 
287

 
3.5

 
847

 
824

 
2.8

     International
 
193

 
180

 
7.2

 
613

 
527

 
16.3

     Worldwide
 
490

 
467

 
4.9

 
1,460

 
1,351

 
8.1

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
35

 
51

 
(31.4
)
 
117

 
152

 
(23.0
)
     International
 
96

 
101

 
(5.0
)
 
302

 
329

 
(8.2
)
     Worldwide
 
131

 
152

 
(13.8
)
 
419

 
481

 
(12.9
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
651

 
647

 
0.6

 
1,914

 
1,931

 
(0.9
)
     International
 
839

 
851

 
(1.4
)
 
2,663

 
2,531

 
5.2

     Worldwide
 
1,490

 
1,498

 
(0.5
)
 
4,577

 
4,462

 
2.6

     CONCERTA® / Methylphenidate
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
57

 
100

 
(43.0
)
 
191

 
284

 
(32.7
)
     International
 
100

 
98

 
2.0

 
322

 
304

 
5.9

     Worldwide
 
157

 
198

 
(20.7
)
 
513

 
588

 
(12.8
)
     INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
468

 
395

 
18.5

 
1,306

 
1,154

 
13.2

     International
 
281

 
248

 
13.3

 
859

 
722

 
19.0

     Worldwide
 
749

 
643

 
16.5

 
2,165

 
1,876

 
15.4

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
76

 
87

 
(12.6
)
 
238

 
273

 
(12.8
)
     International
 
99

 
107

 
(7.5
)
 
321

 
335

 
(4.2
)
     Worldwide
 
175

 
194

 
(9.8
)
 
559

 
608

 
(8.1
)
 
 
 
 
 
 
 
 
 
 
 
 
 
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
50

 
65

 
(23.1
)
 
179

 
220

 
(18.6
)
     International
 
359

 
398

 
(9.8
)
 
1,161

 
1,170

 
(0.8
)
     Worldwide
 
409

 
463

 
(11.7
)
 
1,340

 
1,390

 
(3.6
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,250

 
846

 
47.8

 
3,268

 
2,207

 
48.1

     International
 
1,338

 
1,052

 
27.2

 
4,087

 
3,012

 
35.7

     Worldwide
 
2,588

 
1,898

 
36.4

 
7,355

 
5,219

 
40.9

     DARZALEX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
318

 
230

 
38.3

 
880

 
643

 
36.9

     International
 
180

 
87

 
*
 
561

 
228

 
*
     Worldwide
 
498

 
317

 
57.1

 
1,441

 
871

 
65.4

     IMBRUVICA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
334

 
230

 
45.2

 
811

 
622

 
30.4

     International
 
371

 
282

 
31.6

 
1,101

 
749

 
47.0

     Worldwide
 
705

 
512

 
37.7

 
1,912

 
1,371

 
39.5

     VELCADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—

 
—

     International
 
271

 
273

 
(0.7
)
 
864

 
843

 
2.5

     Worldwide
 
271

 
273

 
(0.7
)
 
864

 
843

 
2.5

     ZYTIGA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
527

 
352

 
49.7

 
1,420

 
826

 
71.9

     International
 
431

 
317

 
36.0

 
1,292

 
924

 
39.8

     Worldwide
 
958

 
669

 
43.2

 
2,712

 
1,750

 
55.0

     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
71

 
34

 
*
 
157

 
116

 
35.3

     International
 
85

 
93

 
(8.6
)
 
269

 
268

 
0.4

     Worldwide
 
156

 
127

 
22.8

 
426

 
384

 
10.9

 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary Hypertension
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
425

 
371

 
14.6
 
1,215

 
408

 
*
     International
 
231

 
261

 
(11.5)
 
691

 
309

 
*
     Worldwide
 
656

 
632

 
3.8
 
1,906

 
717

 
*
     OPSUMIT®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
182

 
150

 
21.3
 
511

 
174

 
*
     International
 
128

 
109

 
17.4
 
381

 
130

 
*
     Worldwide
 
310

 
259

 
19.7
 
892

 
304

 
*
     TRACLEER®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
69

 
83

 
(16.9)
 
208

 
85

 
*
     International
 
70

 
127

 
(44.9)
 
214

 
151

 
*
     Worldwide
 
139

 
210

 
(33.8)
 
422

 
236

 
*
     UPTRAVI®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
154

 
113

 
36.3
 
433

 
121

 
*
     International
 
17

 
11

 
54.5
 
49

 
12

 
*
     Worldwide
 
171

 
124

 
37.9
 
482

 
133

 
*
     OTHER 
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
20

 
25

 
(20.0)
 
63

 
28

 
*
     International
 
16

 
14

 
14.3
 
47

 
16

 
*
     Worldwide
 
36

 
39

 
(7.7)
 
110

 
44

 
*
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,026

 
1,179

 
(13.0
)
 
3,230

 
3,488

 
(7.4
)
     International
 
365

 
406

 
(10.1
)
 
1,196

 
1,177

 
1.6

     Worldwide
 
1,391

 
1,585

 
(12.2
)
 
4,426

 
4,665

 
(5.1
)
     XARELTO®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
612

 
635

 
(3.6
)
 
1,869

 
1,790

 
4.4

     International
 
—

 
—

 
—

 
—

 
—

 
—

     Worldwide
 
612

 
635

 
(3.6
)
 
1,869

 
1,790

 
4.4

     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
150

 
220

 
(31.8
)
 
523

 
723

 
(27.7
)
     International
 
40

 
45

 
(11.1
)
 
130

 
121

 
7.4

     Worldwide
 
190

 
265

 
(28.3
)
 
653

 
844

 
(22.6
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
178

 
168

 
6.0

 
523

 
511

 
2.3

     International
 
77

 
70

 
10.0

 
244

 
229

 
6.6

     Worldwide
 
255

 
238

 
7.1

 
767

 
740

 
3.6

     OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
86

 
156

 
(44.9
)
 
315

 
464

 
(32.1
)
     International
 
248

 
291

 
(14.8
)
 
822

 
827

 
(0.6
)
     Worldwide
 
334

 
447

 
(25.3
)
 
1,137

 
1,291

 
(11.9
)
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
6,097

 
5,816

 
4.8

 
17,350

 
15,698

 
10.5

     International
 
4,249

 
3,879

 
9.5

 
13,194

 
10,877

 
21.3

     Worldwide
 
10,346

 
9,695

 
6.7

 
30,544

 
26,575

 
14.9

 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
125

 
168

 
(25.6
)
 
371

 
482

 
(23.0
)
     International
 
190

 
237

 
(19.8
)
 
638

 
743

 
(14.1
)
     Worldwide
 
315

 
405

 
(22.2
)
 
1,009

 
1,225

 
(17.6
)
Diagnostics
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—

 
—

     International
 
—

 
—

 
—

 
—

 
1

 
*
     Worldwide
 
—

 
—

 
—

 
—

 
1

 
*
Interventional Solutions
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
320

 
279

 
14.7

 
947

 
843

 
12.3

     International
 
333

 
274

 
21.5

 
1,013

 
832

 
21.8

     Worldwide
 
653

 
553

 
18.1

 
1,960

 
1,675

 
17.0

Orthopaedics
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,284

 
1,308

 
(1.8
)
 
3,923

 
4,034

 
(2.8
)
     International
 
827

 
896

 
(7.7
)
 
2,700

 
2,738

 
(1.4
)
     Worldwide
 
2,111

 
2,204

 
(4.2
)
 
6,623

 
6,772

 
(2.2
)
 
 
 
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
201

 
195

 
3.1

 
621

 
612

 
1.5

     International
 
129

 
133

 
(3.0
)
 
432

 
418

 
3.3

     Worldwide
 
330

 
328

 
0.6

 
1,053

 
1,030

 
2.2

     KNEES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
215

 
220

 
(2.3
)
 
672

 
702

 
(4.3
)
     International
 
126

 
123

 
2.4

 
438

 
424

 
3.3

     Worldwide
 
341

 
343

 
(0.6
)
 
1,110

 
1,126

 
(1.4
)
     TRAUMA
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
395

 
398

 
(0.8
)
 
1,196

 
1,179

 
1.4

     International
 
259

 
264

 
(1.9
)
 
829

 
768

 
7.9

     Worldwide
 
654

 
662

 
(1.2
)
 
2,025

 
1,947

 
4.0

     SPINE & OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
473

 
495

 
(4.4
)
 
1,434

 
1,541

 
(6.9
)
     International
 
313

 
376

 
(16.8
)
 
1,001

 
1,128

 
(11.3
)
     Worldwide
 
786

 
871

 
(9.8
)
 
2,435

 
2,669

 
(8.8
)
Surgery
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,016

 
1,002

 
1.4

 
3,031

 
3,009

 
0.7

     International
 
1,360

 
1,344

 
1.2

 
4,283

 
3,992

 
7.3

     Worldwide
 
2,376

 
2,346

 
1.3

 
7,314

 
7,001

 
4.5

     ADVANCED
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
421

 
398

 
5.8

 
1,216

 
1,190

 
2.2

     International
 
555

 
525

 
5.7

 
1,731

 
1,543

 
12.2

     Worldwide
 
976

 
923

 
5.7

 
2,947

 
2,733

 
7.8

     GENERAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
423

 
430

 
(1.6
)
 
1,282

 
1,276

 
0.5

     International
 
657

 
675

 
(2.7
)
 
2,094

 
2,017

 
3.8

     Worldwide
 
1,080

 
1,105

 
(2.3
)
 
3,376

 
3,293

 
2.5

     SPECIALTY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
172

 
174

 
(1.1
)
 
533

 
543

 
(1.8
)
     International
 
148

 
144

 
2.8

 
458

 
432

 
6.0

     Worldwide
 
320

 
318

 
0.6

 
991

 
975

 
1.6

Vision
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
452

 
432

 
4.6

 
1,351

 
1,142

 
18.3

     International
 
680

 
659

 
3.2

 
2,069

 
1,802

 
14.8

     Worldwide
 
1,132

 
1,091

 
3.8

 
3,420

 
2,944

 
16.2

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
319

 
302

 
5.6

 
948

 
832

 
13.9

     International
 
516

 
498

 
3.6

 
1,538

 
1,404

 
9.5

     Worldwide
 
835

 
800

 
4.4

 
2,486

 
2,236

 
11.2

     SURGICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
133

 
130

 
2.3

 
403

 
310

 
30.0

     International
 
164

 
161

 
1.9

 
531

 
398

 
33.4

     Worldwide
 
297

 
291

 
2.1

 
934

 
708

 
31.9

 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,197

 
3,189

 
0.3

 
9,623

 
9,510

 
1.2

     International
 
3,390

 
3,410

 
(0.6
)
 
10,703

 
10,108

 
5.9

     Worldwide
 
6,587

 
6,599

 
(0.2
)
 
20,326

 
19,618

 
3.6

 
 
 
 
 
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
10,664

 
10,290

 
3.6

 
31,255

 
29,394

 
6.3

     International
 
9,684

 
9,360

 
3.5

 
29,932

 
26,861

 
11.4

     Worldwide
 
$
20,348

 
19,650

 
3.6
 %
 
$
61,187

 
56,255

 
8.8
 %

*Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business
EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 
 
Fiscal Third Quarters Ended
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 30,
2018
 
October 1,
2017
 
Percent
Change
 
September 30,
2018
 
October 1,
2017
 
Percent Change
Consumer (1)
 
$
510

 
878

 
(41.9
)%
 
$
1,887

 
2,132

 
(11.5
)%
Pharmaceutical(2)
 
2,876

 
2,857

 
0.7

 
10,193

 
9,934

 
2.6

Medical Devices(3)
 
1,267

 
1,383

 
(8.4
)
 
3,642

 
3,938

 
(7.5
)
Segment earnings before provision for taxes
 
4,653

 
5,118

 
(9.1
)
 
15,722

 
16,004

 
(1.8
)
Less: Expense not allocated to segments (4)
 
230

 
328

 
 
 
845

 
891

 
 

Worldwide income before tax
 
$
4,423

 
4,790

 
(7.7
)%
 
$
14,877

 
15,113

 
(1.6
)%

(1) Includes a gain of $0.3 billion from the divestiture of NIZORAL® in the fiscal nine months of 2018. Includes a gain of $0.4 billion from the divestiture of COMPEED® in the fiscal third quarter and fiscal nine months of 2017. Includes amortization expense of $0.1 billion in the fiscal third quarters and $0.2 billion in fiscal nine months of 2018 and 2017.
 
(2) Includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion in the fiscal third quarter and fiscal nine months of 2018. Includes Actelion acquisition related costs of $0.4 billion in the fiscal third quarter of 2017. Includes Actelion acquisition related costs of $0.2 billion and $0.6 billion in the fiscal nine months of 2018 and 2017, respectively. Includes a gain of $0.1 billion from the divestiture of PANCREASE® in the fiscal nine months of 2018. Includes a gain of $0.2 billion related to monetization of future royalty receivables in the fiscal nine months of 2017. Includes a gain of $0.3 billion in the fiscal nine months of 2017 related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes litigation expense of $0.1 billion in the fiscal nine months of 2017. Includes amortization expense of $0.7 billion in the fiscal third quarters of 2018 and 2017. Includes amortization expense of $2.3 billion and $0.9 billion in the fiscal nine months of 2018 and 2017, respectively.
(3) Includes a restructuring related charge of $0.2 billion and $0.2 billion in the fiscal third quarters of 2018 and 2017, respectively. Includes a restructuring related charge of $0.4 billion and $0.5 billion in the fiscal nine months of 2018 and 2017, respectively. Includes litigation expense of $0.1 billion in the fiscal third quarter of 2017. Includes litigation expense of $0.7 billion and $0.5 billion in the fiscal nine months of 2018 and 2017, respectively. Includes an asset impairment of $0.2 billion primarily related to the insulin pump business in the fiscal nine months of 2017. Includes amortization expense of $0.3 billion and $0.3 billion in the fiscal third quarters of 2018 and 2017, respectively. Includes amortization expense of $0.8 billion and $0.8 billion in the fiscal nine months of 2018 and 2017, respectively.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
SALES BY GEOGRAPHIC AREA
 
 
Fiscal Third Quarters Ended
 
Fiscal Nine Months Ended
(Dollars in Millions)
 
September 30, 2018
 
October 1, 2017
 
Percent
Change
 
September 30, 2018
 
October 1, 2017
 
Percent Change
United States
 
$
10,664

 
10,290

 
3.6
 %
 
$
31,255

 
29,394

 
6.3
%
Europe
 
4,416

 
4,308

 
2.5

 
14,023

 
12,398

 
13.1

Western Hemisphere, excluding U.S.
 
1,550

 
1,569

 
(1.2
)
 
4,657

 
4,522

 
3.0

Asia-Pacific, Africa
 
3,718

 
3,483

 
6.7

 
11,252

 
9,941

 
13.2

Total
 
$
20,348

 
19,650

 
3.6
 %
 
$
61,187

 
56,255

 
8.8
%